- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
XORTX Therapeutics (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease and rare diseases such as autosomal dominant polycystic kidney disease. As quoted in the press release: At the present time, despite considerable effort, very …
XORTX Therapeutics (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease and rare diseases such as autosomal dominant polycystic kidney disease.
As quoted in the press release:
At the present time, despite considerable effort, very few approved therapeutic options exist to treat progressive kidney disease. There is reason for hope, however. Based on recent clinical study evidence, the presence of uric acid above the normal range can act to negatively affect the health and therapeutic outcomes of patients with PKD.  The PKD Foundation is supportive of new treatments to lower and maintain uric acid levels in patients. Towards this goal, the PKD Foundation will make available its scientific expertise to support and collaborate with XORTX to discover these new treatments.
Dr. David Baron, Chief Scientific Officer, PKD Foundation stated, “We believe that the combination of the PKD Foundation’s and XORTX’s scientific expertise may enable an entirely new class of highly active and potentially important treatments for patients for whom current biopharmaceutical approaches have had limited success.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â